884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies. - Teichner, Paula; Cutrell, Amy; D'Amico, Ronald; Dorey, David; Griffith, Sandy; Harrington, Conn M; Huang, Jenny; Hudson, Krischan J; Margolis, David; Mrus, Joseph; Polli, Joseph; Spreen, William; et al. (Open Forum Infectious Diseases, 2019)